Lieb Klaus, Koch Cora
University Medical Center Mainz, Department of Psychiatry and Psychotherapy, Mainz, Germany.
Westfälische Wilhelms-University of Münster, Münster, Germany.
GMS Z Med Ausbild. 2014 Feb 17;31(1):Doc10. doi: 10.3205/zma000902. eCollection 2014.
Medical students interact with pharmaceutical representatives already during medical school. The goal of this study was to find out: Do policies exist at German medical faculties that govern the interactions between medical students and pharmaceutical representatives, do schools offer courses on the subject and do students attend these courses? And What are the attitudes of medical students concerning the role of pharmaceutical companies in medical teaching?
All 36 German medical faculty deans and 1151 medical students at eight German universities were asked to complete a questionnaire of 4 and 7 questions, respectively, regarding the above mentioned topics.
30 (83.3%) deans and 1038 (90.3%) medical students filled in the questionnaire, respectively. According to the deans' answers, only one school had a policy concerning conflicts of interest and one had a policy governing the interactions between medical students and industry. 8 (26.7%) deans showed an interest in constructing a policy or educational an activity on this subject. 149 (14.4%) students had participated in an activity that focussed the subject of conflicts of interest and 779 (77.8%) wanted more education on the subject. 701 (73.4%) were opposed to an improvement of medical studies through financial support by pharmaceutical companies, whereas 216 (21.9%) were of the opinion that students should not meet with pharmaceutical representatives.
Unlike in other countries, like the US, most German medical faculties do not have policies that govern the interactions between medical students and pharmaceutical companies. Since most students want to be taught more about these interactions, the implementation of respective policies and lectures would be desirable.
医学生在医学院学习期间就已经与医药代表有互动。本研究的目的是查明:德国医学院是否存在管理医学生与医药代表互动的政策,学校是否开设关于该主题的课程以及学生是否参加这些课程?医学生对制药公司在医学教学中的作用持何种态度?
分别向德国所有36位医学院院长和8所德国大学的1151名医学生发放问卷,问卷分别包含4个和7个关于上述主题的问题。
分别有30位(83.3%)院长和1038名(90.3%)医学生填写了问卷。根据院长们的回答,只有一所学校有关于利益冲突的政策,一所学校有管理医学生与行业互动的政策。8位(26.7%)院长表示有兴趣制定关于该主题的政策或开展相关教育活动。149名(14.4%)学生参加过聚焦利益冲突主题的活动,779名(77.8%)学生希望接受更多关于该主题的教育。701名(73.4%)学生反对制药公司通过资金支持来改善医学研究,而216名(21.9%)学生认为学生不应与医药代表会面。
与美国等其他国家不同,大多数德国医学院没有管理医学生与制药公司互动的政策。由于大多数学生希望更多地了解这些互动,因此实施相应的政策和开展讲座是可取的。